AIM:To compare the visual refractive outcome and complication of laser in situ keratomileusis (LASIK) treated with 5g/L loteprednol etabonate and 1g/L fluorometholone ophthalmic suspension after operation. ·METHODS:Totally 160 consecutive eyes that received 5g/L loteprednol etabonate ophthalmic suspension(group A) and 1g/L fluorometholone ophthalmic suspension (group B) after LASIK were reviewed. Manifest refrac-tion,uncorrected visual acuity(UCVA),best spectacle-corrected visual acuity (BSCVA),and intraocular pres-sure (IOP) were recorded before and 1 day,1 week,1 month,3 months after treatment.Diffuse lamellar keratitis (DLK),postoperative complications,and frequency of retreatments were observed. ·RESULTS:There was no difference in manifest refraction,UCVA,BSCVA and DLK after operation between two groups. Preoperatively IOP didn’t differ significantly between two groups. IOP in group A and B were 13.3±3.5mmHg and 16.4±4.9mmHg respectively 3 months after operation. IOP in group A was lower significantly than the later. ·CONCLUSION:Loteprednol etabonate ophthalmic suspension 5g/L can suppress the inflammation response caused by LASIK effectively. Compared with traditional steroid suspension,5g/L Etabonate ophthalmic suspen-sion can obviously reduce occurrence of high IOP.